article · Foods
Metabolic syndrome has become a widespread public health issue driven by obesity, physical inactivity, poor diets, and aging populations. Ellagitannins, which are hydrolysable tannins, and their breakdown products show biological activities that address several central mechanisms of the condition. These mechanisms include oxidative stress, chronic inflammation, insulin resistance, endothelial dysfunction, and impaired lipid metabolism. A comparative evaluation of these natural compounds indicates that punicalagin and geraniin currently hold the most robust preclinical evidence, consistently demonstrating positive effects across multiple cellular and animal studies. Other compounds, including chebulagic acid, corilagin, chebulinic acid, and punicalin, show substantial therapeutic potential but require broader validation across different experimental setups. Combining multiple ellagitannins may also produce synergistic interactions that offer wider pharmacological benefits against metabolic syndrome.
Metabolic syndrome increases the risk of serious conditions such as cardiovascular disease and type 2 diabetes. Understanding how natural plant-derived compounds can target the underlying biological disruptions offers opportunities to design safer, supportive dietary interventions and treatments that mitigate the growing global burden of lifestyle-related metabolic disorders.
This research provides early-stage targets for nutraceutical, functional food, and pharmaceutical developers addressing metabolic disorders. Punicalagin and geraniin are the most immediate candidates for continued pipeline development, though all findings remain at an early preclinical stage based on cell and animal models. Bringing these compounds to market will require further experimental validation, exploration of synergistic formulations, and formal clinical safety and efficacy trials.
AI-generated from the published abstract. Always read the original work before citing.
Over the years, metabolic syndrome (MetS) has emerged as one of the most significant public health challenges, driven by the global increase in obesity, physical inactivity, unhealthy dietary patterns, and population aging. Ellagitannins are a class of hydrolysable tannins that have emerged as promising natural bioactive compounds, owing to their broad spectrum of biological activities. Increasing evidence suggests that some ellagitannins and their metabolites modulate several pathogenic mechanisms underlying metabolic syndrome, including oxidative stress, chronic inflammation, insulin resistance, endothelial dysfunction, and dysregulated lipid metabolism. This work reviews the pharmacological activities and therapeutic prospects of ellagitannins in the management of metabolic syndrome-related disorders. It further provides a critical and comparative analysis of the pharmacological profiles of reported ellagitannins, offering insights into their therapeutic efficacy and potential synergistic applications in the management of MetS-related disorders. Overall, Punicalagin and Geraniin currently possess the strongest preclinical evidence, supported by multiple independent studies employing both cellular and animal models that consistently demonstrate beneficial effects across several components of MetS. Chebulagic acid, Corilagin, Chebulinic acid, and Punicalin also show considerable promise but require further validation in diverse experimental systems. Potential synergistic interactions among ellagitannins when administered in combination should be investigated for enhanced therapeutic efficacy and broader multifaceted pharmacological effects.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/foods15173114
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
